Anti-Inflammatory Biologics Market Report 2026

Anti-Inflammatory Biologics Market Overview

• Anti-Inflammatory Biologics market size has reached to $118.02 billion in 2025 • Expected to grow to $180.93 billion in 2030 at a compound annual growth rate (CAGR) of 8.9% • Growth Driver: Rising Prevalence Of Arthritis Fueling The Growth Of The Market Due To Increasing MSK Disease Burden • Market Trend: Targeted IL-6 Therapies Offer Safer Relief For Chronic Inflammatory Conditions • North America was the largest region in 2025 and Europe is the fastest growing region.

What Is Covered Under Anti-Inflammatory Biologics Market?

Anti-inflammatory biologics are therapeutic drugs derived from living organisms that target specific components of the immune system to reduce inflammation. They are commonly used to treat chronic inflammatory conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease by inhibiting cytokines or immune cells responsible for the inflammatory response. The main drug classes of anti-inflammatory biologics are tumor necrosis factor inhibitors, interleukin inhibitors, B-cell inhibitors, T-cell inhibitors, and others. Tumor necrosis factor inhibitors are a class of biologic drugs that block the activity of tumor necrosis factor-alpha, a substance in the body that causes inflammation, to help reduce symptoms in autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease. These medications are administered through various routes of administration such as oral, injection, intravenous, and subcutaneous. They are commonly used for a range of applications, including rheumatoid arthritis, inflammatory bowel disease, psoriasis, and others, and are provided through multiple distribution channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others. They serve a diverse group of end users such as hospitals, clinics, home care settings, and research and academic institutes.

What Is The Anti-Inflammatory Biologics Market Growth Forecast?

The anti-inflammatory biologics market size is expected to see strong growth in the next few years. It will grow to $180.93 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to development of next-generation cytokine inhibitors, expansion of home care and self-administration options, increasing regulatory approvals and faster clinical trial processes, rising investment in precision medicine and biologics R&D, growing partnerships between pharma and biotech companies. Major trends in the forecast period include rising adoption of targeted biologics for chronic inflammatory diseases, expansion of subcutaneous and injectable drug delivery, growing clinical trials and research for novel anti-inflammatory biologics, increased focus on personalized treatment plans, rising awareness and access to biologics in emerging markets.

Global Anti-Inflammatory Biologics Market Segmentation

1) By Drug Class: Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, B-Cell Inhibitors, T-Cell Inhibitors, Other Drug Classes 2) By Route Of Administration: Oral, Injection, Intravenous, Subcutaneous 3) By Application: Rheumatoid Arthritis, Inflammatory Bowel Disease, Psoriasis, Other Applications 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels 5) By End-Users: Hospital, Clinics, Home Care Settings, Research And Academic Institutes Subsegments: 1) By Tumor Necrosis Factor Inhibitors: Adalimumab, Infliximab, Etanercept, Golimumab, Certolizumab Pegol 2) By Interleukin Inhibitors: Interleukin-1 Inhibitors, Interleukin-6 Inhibitors, Interleukin -12 Or 23 Inhibitors, Interleukin -17 Inhibitors, Interleukin -23 Inhibitors 3) By B-Cell Inhibitors: Rituximab, Ocrelizumab, Ofatumumab 4) By T-Cell Inhibitors: Abatacept, Alefacept 5) By Other Drug Classes: Janus Kinase Inhibitors, Anti-IgE And Other Biologics

What Is The Driver Of The Anti-Inflammatory Biologics Market?

The rising prevalence of arthritis is expected to propel the growth of the anti-inflammatory biologics market going forward. Arthritis refers to inflammation or swelling of one or more joints, causing pain, stiffness, and reduced movement, often worsening with age. The rising prevalence of arthritis is primarily due to increasing obesity rates, as excess body weight places additional stress on joints, leading to inflammation and joint degeneration. Anti-inflammatory biologics are useful for arthritis by targeting specific components of the immune system to reduce inflammation, slow joint damage, relieve symptoms, and improve physical function and quality of life for people with moderate to severe arthritis. For instance, in January 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, in 2023, 18.4% of people aged 16 and over reported having a long-term MSK condition, up from 17.6% in 2022. Therefore, the rising prevalence of arthritis is driving the growth of the anti-inflammatory biologics industry.

Key Players In The Global Anti-Inflammatory Biologics Market

Major companies operating in the anti-inflammatory biologics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, AbbVie Inc, Sanofi S.A, Bristol-Myers Squibb, Novartis AG, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc, UCB S.A

Global Anti-Inflammatory Biologics Market Trends and Insights

Major companies operating in the anti-inflammatory biologics market are focusing on developing innovative solutions, such as interleukin-6 (IL-6) receptor antagonists, to target chronic inflammatory diseases with greater specificity and reduced side effects. Interleukin-6 (IL-6) receptor antagonists are biologic drugs that block the IL-6 receptor to reduce inflammation and immune response in conditions such as rheumatoid arthritis. For instance, in February 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, received approval from the US Food and Drug Administration (FDA) for Kevzara as the first and only biologic treatment indicated for patients with polymyalgia rheumatica (PMR) who do not respond adequately to corticosteroids. Kevzara is a fully human monoclonal antibody that blocks the IL-6 receptor, helping to reduce inflammation linked to PMR, a condition that causes muscle pain and stiffness, mainly in older adults. Unlike traditional steroids, which carry risks such as osteoporosis and diabetes with prolonged use, Kevzara provides a more targeted, steroid-sparing approach that supports improved patient outcomes and enhanced long-term safety.

What Are Latest Mergers And Acquisitions In The Anti-Inflammatory Biologics Market?

In October 2023, Amgen Inc., a U.S.-based biopharmaceutical company, acquired Horizon Therapeutics plc for $27.8 billion. With this acquisition, Amgen aims to strengthen its leadership in innovative medicines for serious diseases, particularly by expanding its portfolio in rare and autoimmune conditions, accelerating growth, and reaching more patients worldwide with first-in-class therapies. Horizon Therapeutics plc is an Ireland-based company that is developing several anti-inflammatory biologics.

Regional Insights

North America was the largest region in the anti-inflammatory biologics market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Anti-Inflammatory Biologics Market?

The anti-inflammatory biologics market consists of sales of adalimumab, etanercept, infliximab, ustekinumab, and secukinumab. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Anti-Inflammatory Biologics Market Report 2026?

The anti-inflammatory biologics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the anti-inflammatory biologics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.